Similar articles

• Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER).

  Cho EA, Moloney FJ, Cai H, Au-Yeung A, China C, Scolyer RA, Yosufi B, Raftery MJ, Deng JZ, Morton SW, Hammond PT, Arkenau HT, Damian DL, Francis DJ, Chesterman CN, Barnetson RS, Halliday GM, Khachigian LM. Cho EA, et al. Lancet. 2013 May 25;381(9880):1835-43. doi: 10.1016/S0140-6736(12)62166-7. Epub 2013 May 7. Lancet. 2013. PMID: 23660123 Free PMC article. Clinical Trial.
• [Evidence-based medicine: Analysis of the randomized trial "imiquimod vs. surgery for basal cell carcinoma"].

  Guillot B. Guillot B. Ann Dermatol Venereol. 2015 May;142(5):369-70. doi: 10.1016/j.annder.2015.01.008. Epub 2015 Mar 3. Ann Dermatol Venereol. 2015. PMID: 25749512 French. No abstract available.
• Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma.

  Shulstad RM. Shulstad RM. Dermatol Nurs. 2009 Mar-Apr;21(2):86-7. Dermatol Nurs. 2009. PMID: 19507375
• Topical and light-based treatments for basal cell carcinoma.

  Robinson JK, Hernandez C, Anderson ER, Nickoloff B. Robinson JK, et al. Semin Cutan Med Surg. 2003 Sep;22(3):171-6. doi: 10.1016/S1085-5629(03)00047-6. Semin Cutan Med Surg. 2003. PMID: 14649584 Review.
• Topical therapy in the treatment of actinic keratosis and basal cell carcinoma.

  Newman MD, Weinberg JM. Newman MD, et al. Cutis. 2007 Apr;79(4 Suppl):18-28. Cutis. 2007. PMID: 17508492 Review.